Abstract:In the past five years, our team had been committed to click chemistry research, exploring the biological activity of 1,2,3-triazole by synthesizing different target inhibitors. In this study, a series of novel indole-2-one derivatives based on 1,2,3-triazole scaffolds were synthesized for the first time, and their inhibitory activity on vascular endothelial growth factor receptor-2 (VEGFR-2) was tested. Most of the compounds had shown promising activity in the VEGFR-2 kinase assay and had low toxicity to human umbilical vein endothelial cells (HUVECs). The compound 13d (IC50 = 26.38 nM) had better kinase activity inhibition ability than sunitinib (IC50 = 83.20 nM) and was less toxic to HUVECs. Moreover, it had an excellent inhibitory effect on HT-29 and MKN-45 cells. On the one hand, by tube formation assay, transwell, and western blot analysis, compound 13d could inhibit VEGFR-2 protein phosphorylate on HUVECs, thereby inhibiting HUVECs migration and tube formation. In vivo study, the zebrafish model with VEGFR-2 labeling also verified that compound 13d had more anti-angiogenesis ability than sunitinib. On the other hand, molecular docking and molecular dynamics (MD) simulation results showed that compound 13d could stably bind to the active site of VEGFR-2. Based on the above findings, compound 13d could be considered an effective anti-angiogenesis drug and has more development value than sunitinib.

Discovery of Novel Anti-Angiogenesis Agents. Part 10: Multi-target Inhibitors of VEGFR-2, Tie-2 and EphB4 Incorporated with 1,2,3-Triazol

Discovery of Novel Anti-Angiogenesis Agents. Part 7: Multitarget Inhibitors of VEGFR-2, TIE-2 and EphB4.

Discovery of Novel Anti-Angiogenesis Agents. Part 6: Multi-targeted RTK Inhibitors

Discovery of Novel Anti-Angiogenesis Agents. Part 8: Diaryl Thiourea Bearing 1H-Indazole-3-amine As Multi-Target RTKs Inhibitors

Discovery of Novel Anti-Angiogenesis Agents. Part 9: Multiplex Inhibitors Suppressing Compensatory Activations of RTKs

Discovery and Evaluation of Triple Inhibitors of VEGFR-2, TIE-2 and EphB4 As Anti-Angiogenic and Anti-Cancer Agents

Discovery of multi-target receptor tyrosine kinase inhibitors as novel anti-angiogenesis agents

New Application of Novel Tetrazine Derivatives As Potent VEGFR-2 Kinase Inhibitors and Anti-Cancer Agents

Discovery of Novel VEGFR-2 Inhibitors. Part 5: Exploration of Diverse Hinge-Binding Fragments Via Core-Refining Approach

Design, synthesis, and in vitro and in vivo anti-angiogenesis study of a novel vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor based on 1,2,3-triazole scaffold

Discovery of 4,6‐disubstituted Pyrimidine Derivatives As Novel Dual VEGFR2/FGFR1 Inhibitors

Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazo-line and diarylamide fragments

Design and Synthesis of Novel Thiazolo[5,4‐d]pyrimidine Derivatives As Potential Angiogenesis Inhibitors

Discovery of novel amide derivatives against VEGFR-2/tubulin with potent antitumor and antiangiogenic activity

Discovery of biphenyl-based VEGFR-2 inhibitors. Part 3: design, synthesis and 3D-QSAR studies.

Discovery and Optimization of N-Substituted 2-(4-pyridinyl)thiazole Carboxamides Against Tumor Growth Through Regulating Angiogenesis Signaling Pathways

Phenyl and Diarylureas with Thiazolo [5,4-d]pyrimidine Scaffold as Angiogenesis Inhibitors: Design, Synthesis and Biological Evaluation.

Synthesis and Structure-Activity Relationships of Pyrazine-Pyridine Biheteroaryls As Novel, Potent, and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitors.

Synthesis and biological evaluation of novel oxazolo[5,4-d]pyrimidines as potent VEGFR-2 inhibitors.

Discovery of Biphenyl-Aryl Ureas As Novel VEGFR-2 Inhibitors. Part 4: Exploration of Diverse Hinge-Binding Fragments

Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors